Tech Company Financing Transactions
Eradivir Funding Round
Eradivir, based in West Lafayette, secured $10.3 million from private investors.
Transaction Overview
Company Name
Announced On
9/26/2024
Transaction Type
Venture Equity
Amount
$10,250,000
Round
Series A
Investors
private investors (Philip Low)
Proceeds Purpose
The company intends to use the funds to conduct a Phase 2a challenge study of its EV25 influenza treatment.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1281 Win Hentschel Boulevard
West Lafayette, IN 47906
USA
West Lafayette, IN 47906
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Eradivir's founder, Dr. Philip S. Low, has successfully developed multiple FDA-approved targeted small molecules. These therapies all function by attaching various payloads to ligands, which bind with high specificity to diseased cells. Examples of approved molecules include a radiotherapy drug for prostate cancer and an intraoperative imaging agent for lung and ovarian cancers. Several others are currently in clinical trials (e.g., treatments for cancer, malaria, and sickle cell anemia). Eradivir was founded in March 2020 to advance a promising application of this platform in combating multiple disease states, initially focusing on influenza and other respiratory infections.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 9/26/2024: K1x venture capital transaction
Next: 9/26/2024: Cyvatar venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs